Success Metrics

Clinical Success Rate
80.4%

Based on 37 completed trials

Completion Rate
80%(37/46)
Active Trials
1(2%)
Results Posted
41%(15 trials)
Terminated
9(16%)

Phase Distribution

Ph phase_1
17
29%
Ph phase_3
8
14%
Ph phase_2
29
50%
Ph phase_4
1
2%

Phase Distribution

17

Early Stage

29

Mid Stage

9

Late Stage

Phase Distribution55 total trials
Phase 1Safety & dosage
17(30.9%)
Phase 2Efficacy & side effects
29(52.7%)
Phase 3Large-scale testing
8(14.5%)
Phase 4Post-market surveillance
1(1.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.1%

37 of 48 finished

Non-Completion Rate

22.9%

11 ended early

Currently Active

1

trials recruiting

Total Trials

58

all time

Status Distribution
Active(3)
Completed(37)
Terminated(11)
Other(7)

Detailed Status

Completed37
Terminated9
unknown6
Not yet recruiting2
Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
58
Active
1
Success Rate
80.4%
Most Advanced
Phase 4

Trials by Phase

Phase 117 (30.9%)
Phase 229 (52.7%)
Phase 38 (14.5%)
Phase 41 (1.8%)

Trials by Status

not_yet_recruiting23%
completed3764%
recruiting12%
suspended12%
withdrawn23%
terminated916%
unknown610%

Recent Activity

Clinical Trials (58)

Showing 20 of 58 trialsScroll for more
NCT02044354Phase 3

Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer

Completed
NCT06409390Phase 2

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Recruiting
NCT00284778Phase 3

Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer

Completed
NCT07083505Phase 2

A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

Not Yet Recruiting
NCT06925659Phase 1

A Study of QLM2011 in Subjects With Advanced Solid Tumors

Not Yet Recruiting
NCT05207514Phase 3

Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer

Terminated
NCT05863325Phase 2

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Unknown
NCT02324543Phase 1

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Completed
NCT00129896Phase 1

Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

Completed
NCT05705635Phase 2

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

Unknown
NCT04811118Phase 1

The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere

Unknown
NCT01459614Phase 2

Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Completed
NCT03419442

Multi-academic Center Study of Xofigo Patients

Completed
NCT02567383Phase 2

Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer

Unknown
NCT00456989Phase 1

Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer

Completed
NCT00424840Phase 1

Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

Terminated
NCT02187744Phase 3

A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

Completed
NCT02095717Phase 2

Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)

Terminated
NCT00852332Phase 2

Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

Terminated
NCT01796028Phase 2

Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer

Completed

Drug Details

Intervention Type
DRUG
Total Trials
58